Is PT-141 (Bremelanotide) Legal in Ohio? How to Access It Legally
HealthRX.com
Prescription Vyleesi is the approved route; compounded PT-141 is not
Key numbers
- 1.75 mgDose of Vyleesi, the FDA-approved bremelanotide autoinjector sold by prescription onlySource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 40%Share of Vyleesi trial patients who reported nausea, versus about 1% on placeboSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 6 mmHgMaximum transient rise in systolic blood pressure after one Vyleesi doseSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
See the public record for Bremelanotide
At a glance
- FDA status / Bremelanotide is approved as Vyleesi (NDA 210557, June 21, 2019), prescription only [1][3]
- Approved form / 1.75 mg subcutaneous autoinjector, used as needed [1]
- Approved use / Premenopausal women with acquired, generalized HSDD [1]
- Not indicated for / Men, postmenopausal women, or enhancing sexual performance [1]
- Boxed warning / None; no REMS appears in the label or the 2019 approval letter [1][3]
- Compounded PT-141 / Not Vyleesi and not an FDA-approved drug [4]
- Ohio regulator / Ohio Board of Pharmacy [2]
What bremelanotide actually is
PT-141 is another name for bremelanotide. The FDA-approved product is Vyleesi, approved under NDA 210557 on June 21, 2019 and now held by Cosette Pharmaceuticals, supplied as a 1.75 mg subcutaneous autoinjector by prescription only [1][3][5].
The indication is narrow: premenopausal women with acquired, generalized hypoactive sexual desire disorder, meaning low desire that causes marked distress or interpersonal difficulty and is not due to a medical or psychiatric condition, relationship problems, or a medication or drug [1]. The label states it is not indicated for HSDD in postmenopausal women or in men, and not to enhance sexual performance [1].
Where a prescription fits
Vyleesi is prescription only [1]. The Ohio Board of Pharmacy describes itself as the single state agency responsible for administering and enforcing the laws governing pharmacy practice and the legal distribution of drugs in Ohio [2].
The label says to inject 1.75 mg into the abdomen or thigh as needed, at least 45 minutes before anticipated sexual activity. It says not to use more than one dose within 24 hours and does not recommend more than eight doses per month [1].
Questions worth asking
Compounded and research-use PT-141
Products sold as compounded or research-use PT-141 are not Vyleesi and are not FDA-approved drugs, and compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing [1][4].
Bremelanotide does not appear on FDA's page of bulk substances that may present significant safety risks (content dated 04/22/2026) or in any category on FDA's bulk-substance lists, and it is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [6][7][8]. Absence from those lists is not an approval.
What the label says to watch for
Each dose transiently raises blood pressure and lowers heart rate: maximal increases of 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after the dose and usually back to baseline within 12 hours, while a 127-woman ambulatory study showed mean daytime increases of 1.9 mmHg systolic and 1.7 mmHg diastolic [1]. Vyleesi is contraindicated in people with uncontrolled hypertension or known cardiovascular disease [1].
Nausea was reported by 40% of Vyleesi patients versus about 1% on placebo; 13% used anti-nausea medicine and 8% stopped the trials because of it [1]. Focal hyperpigmentation was reported by 1% of patients taking up to 8 doses a month versus none on placebo, and the label says to consider discontinuing Vyleesi if it develops [1].
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
Frequently asked questions
What is PT-141 called when it is prescribed?
Can I buy PT-141 without a prescription in Ohio?
Is compounded PT-141 the same as Vyleesi?
Is bremelanotide approved for men or postmenopausal women?
Does Vyleesi have a boxed warning or a REMS?
Which Ohio agency regulates pharmacies?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
Where can I get PT-141 peptide?
Vyleesi, the FDA-approved form of bremelanotide, is sold by prescription only as a 1.75 mg subcutaneous autoinjector. Products sold as compounded or research-use PT-141 are not Vyleesi and are not FDA-approved drugs, and compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing. The Ohio Board of Pharmacy is the state agency that enforces Ohio drug law.
Is PT-141 available over the counter?
No. Vyleesi requires a prescription. Compounded or research-use PT-141 products are not Vyleesi and are not FDA-approved drugs, so being sold without a prescription does not make them an approved option. Vyleesi is indicated only for premenopausal women with acquired, generalized hypoactive sexual desire disorder.
References
Show all 8 referencesHide references
- U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector prescribing information. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector label
- Ohio Board of Pharmacy.
- U.S. Food and Drug Administration.
- Official web page.
- Drugs@FDA: FDA-Approved Drugs.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- Official web page.